News

While MDMA-AP may be a promising therapy for PTSD,” he continued, “functional unblinding in the clinical trials and additional concerns around trial design and conduct leave many uncertainties about the balance of benefits and harms.

Trailblazer Alert: Melissa Lavasani Featured Among Influential Women in Psychedelics

Cybin Inc., a clinical-stage biopharmaceutical company…announced that the FDA has granted BTD to CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of MDD. If approved by the FDA, CYB003 would be the first known adjunctive psychedelic-based therapeutic for the treatment of MDD.

MindMed has become the fourth organization to be granted FDA Breakthrough Therapy Designation for a psychedelic drug candidate.

Daniel Carcillo, former NHL star, and PMC Board Member, shares his transformative journey from battling severe depression and dementia-like symptoms due to concussions, to finding renewed hope for life through psilocybin therapy.

The FDA has granted the application priority review and has assigned a Prescription Drug User Fee Act ("PDUFA") target action date of August 11, 2024. If approved, this would be the first MDMA-assisted therapy and psychedelic-assisted therapy

Melissa Lavasani, MS, MPP, is a leading voice in the push for legislative reform surrounding psychedelics. She’s committed to improving safe, equitable access to psychedelic medicines through her advocacy work, lobbying efforts, and initiates to educate policymakers.

Join leading experts as they navigate the intricacies of psychedelic treatment, its economic implications, and the policy frontier that will define its role in mental health care

MDMA-assisted therapy becomes the first psychedelic therapy submitted to the FDA for approval

Roland Griffiths, an internationally revered researcher of psychedelic and mood-altering drugs, whose research helped kickstart a new era of psychedelic study and led to the creation of the nation's first psychedelic research center, at Johns Hopkins, died on Monday, Oct. 16, at age 77.

California Governor Gavin Newsom recently vetoed a bill to decriminalize psilocybin.

PMC Founder Melissa Lavasani recently joined Doc Askins’ Anti-Hero’s Journey podcast to share her story and journey in the psychedelic space.

Listen to a captivating conversation between members of our board, Joe Moore from Psychedelics Today and Satya T., a policy expert at Arnold & Porter and PMC advisory board member.

The move makes Australia the first nation to legalize the therapeutic use of psilocybin and MDMA in a controlled medical setting.

Founder, Melissa, was featured on the Green Rush Podcast to discuss the political advancement of psychedelic therapies!

Part of the advocacy process means pushing for more education and changing the narrative.

PMC founder Melissa Lavasani was recently featured on Grassroots Marketing podcast to discuss federal psychedelic legalization!

Rep. Alexandria Ocasio-Cortez and Rep. Dan Crenshaw don’t always agree, but they are on the same side when it comes to helping veterans through psychedelic therapy.

A study from UC Berkeley shows that 61% of Americans support legalizing regulated therapeutic access.

“PMC is the only Washington, D.C.-based member association working on psychedelic medicine policy, and we see this as an opportunity to engage with the U.S. government in a very practical way, and that means lawmakers on both sides of the aisle,” explained Lavasani

There are important legal distinctions between medical, religious, and wellness uses of psychedelic compounds.

Advocates for rescheduling psychedelics like psilocybin, the hallucinogen found in magic mushrooms, to allow for investments in research of the drug, are finding some powerful allies for the cause

Nora Volkow, the director of the National Institute on Drug Abuse (NIDA), said that psychedelic substances have promising potential for therapeutic uses, particularly for treating severe depression, post-traumatic stress disorder (PTSD) and addiction.

COMPASS Pathways and MAPS PBC submitted joint application for new code to facilitate access to psychedelic therapy in the US, if approved

One of the goals of the organization is to influence Congress to develop an entire comprehensive policy outlook. There is a lot of urgency around this issue and it is important to get it right, as it is very challenging to undo bad policies.